Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher T Ritchlin

Showing results (151-160 of 217) with videos related to

Pageof 22
Sort By:
Lancet (London, England)|March 18, 2020
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trialAtul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, et al.
The Journal of Rheumatology|November 3, 2014
Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritisAna-Maria Orbai, Joshua Weitz, Evan L Siegel, et al.
The Journal of Rheumatology|February 12, 2010
Composite measures in psoriatic arthritis: GRAPPA 2008Dafna D Gladman, Robert Landewé, Neil J McHugh, et al.
Lancet (London, England)|February 10, 2020
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trialChristopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, et al.
JCI Insight|August 8, 2024
Psoriatic arthritis subtypes are phenocopied in humanized miceChristopher T Ritchlin, Javier Rangel-Moreno, Delaney Martino, et al.
The Journal of Rheumatology. Supplement|June 3, 2018
Proceedings of the 2017 GRAPPA Collaborative Research Network MeetingDeepak R Jadon, Vinod Chandran, Carmel Stober, et al.
Arthritis and Rheumatism|October 4, 2005
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialPhilip J Mease, Dafna D Gladman, Christopher T Ritchlin, et al.
Archives of Dermatology|February 21, 2007
National Psoriasis Foundation clinical consensus on disease severityDavid M Pariser, Jerry Bagel, Joel M Gelfand, et al.
Frontiers in Immunology|November 24, 2022
Dendritic cell-specific transmembrane protein is required for synovitis and bone resorption in inflammatory arthritisMaria de la Luz Garcia-Hernandez, Javier Rangel-Moreno, Maricela Garcia-Castaneda, et al.
Annals of the Rheumatic Diseases|September 17, 2025
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX studyPhilip J Mease, Christopher T Ritchlin, Laura C Coates, et al.
Pageof 22

Showing results (151-160 of 217) with videos related to

Sort By:
Pageof 22
Lancet (London, England)|March 18, 2020
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trialAtul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, et al.
The Journal of Rheumatology|November 3, 2014
Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritisAna-Maria Orbai, Joshua Weitz, Evan L Siegel, et al.
The Journal of Rheumatology|February 12, 2010
Composite measures in psoriatic arthritis: GRAPPA 2008Dafna D Gladman, Robert Landewé, Neil J McHugh, et al.
Lancet (London, England)|February 10, 2020
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trialChristopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, et al.
JCI Insight|August 8, 2024
Psoriatic arthritis subtypes are phenocopied in humanized miceChristopher T Ritchlin, Javier Rangel-Moreno, Delaney Martino, et al.
The Journal of Rheumatology. Supplement|June 3, 2018
Proceedings of the 2017 GRAPPA Collaborative Research Network MeetingDeepak R Jadon, Vinod Chandran, Carmel Stober, et al.
Arthritis and Rheumatism|October 4, 2005
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialPhilip J Mease, Dafna D Gladman, Christopher T Ritchlin, et al.
Archives of Dermatology|February 21, 2007
National Psoriasis Foundation clinical consensus on disease severityDavid M Pariser, Jerry Bagel, Joel M Gelfand, et al.
Frontiers in Immunology|November 24, 2022
Dendritic cell-specific transmembrane protein is required for synovitis and bone resorption in inflammatory arthritisMaria de la Luz Garcia-Hernandez, Javier Rangel-Moreno, Maricela Garcia-Castaneda, et al.
Annals of the Rheumatic Diseases|September 17, 2025
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX studyPhilip J Mease, Christopher T Ritchlin, Laura C Coates, et al.
Pageof 22